Home › Companies › BLUEPRINT MEDICINES CORP. › 2024-2025

BLUEPRINT MEDICINES CORP. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BLUEPRINT MEDICINES CORP.’s Form 8-K, filed 2025-06-20 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Ballot items
371Asset managers
2,538Fund votes
2025-06-18Meeting date

Proxy season: 2023-2024 2024-2025

Explore BLUEPRINT MEDICINES CORP. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BLUEPRINT MEDICINES CORP.

These tallies are BLUEPRINT MEDICINES CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BLUEPRINT MEDICINES CORP. — official shareholder meeting results, meeting held 2025-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jeffery W. Albers	44,683,223	--	--	15,507,415	2,342,656	Majority: yes
Elect Director: Mark Goldberg, M.D.	46,734,594	--	--	13,456,044	2,342,656	Majority: yes
Elect Director: John Tsai, M.D.	47,572,890	--	--	12,617,748	2,342,656	Majority: yes
2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.	57,714,069	2,450,825	25,744	--	2,342,656	Passed
3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.	62,209,853	288,580	34,861	--	--	Passed

Source: BLUEPRINT MEDICINES CORP., Form 8-K, filed with the SEC on 2025-06-20 — read the filing on EDGAR.

How asset managers voted at the BLUEPRINT MEDICINES CORP. 2024-2025 meeting

Each item below shows how the 371 asset managers that disclosed a BLUEPRINT MEDICINES CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2025-06-18.

Combines 10 wordings of this item as funds reported it.

96% Passed · of votes cast

FOR 96%

FOR: 57,714,069AGAINST: 2,450,825

BLUEPRINT MEDICINES CORP.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 57,714,069 for, 2,450,825 against — passed, per its Form 8-K filed 2025-06-20 (Item 5.07). Of all 64,582,163 outstanding shares: 89% for, 4% against (93% of the company cast a for/against vote).

The 367 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 96%

FOR: 96.0%AGAINST: 3.9%ABSTAIN: 0.1%NOT VOTED: 0.0%

Largest asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	12,987,831	0	For
Vanguard	8,557,184	3	For
BlackRock	4,842,790	0	For
JPMorgan	4,789,526	0	For
Avoro Capital Advisors LLC	3,863,022	0	For
Fidelity	3,595,489	0	For
State Street	3,562,860	3,913	For
Wellington	2,595,811	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,532,467	0	For
AllianceBernstein	1,477,358	0	For
Invesco	0	1,361,935	Against
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	1,228,220	0	For
Charles Schwab	1,222,396	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,167,237	0	For
American Century	0	971,134	Against
Delaware/Macquarie	955,278	0	For
Hood River Capital Management LLC	889,570	0	For
Rock Springs Capital Management LP	865,256	0	For
MUTUAL FUND SERIES TRUST	859,462	0	For
PICTET ASSET MANAGEMENT SA	772,960	0	For
Clearbridge Investments, LLC	673,915	0	For
Nuveen	629,499	0	For
Siren, L.L.C.	623,870	0	For
TIAA	543,598	0	For
Northern Trust	529,272	0	For

Showing the 25 largest of 367 asset managers. See all 367 in the interactive database.

2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDCompany result: Passed

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

99.5% Passed · of votes cast

FOR 99.5%

FOR: 62,209,853AGAINST: 288,580

BLUEPRINT MEDICINES CORP.’s own tally for this item (“3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.”): 62,209,853 for, 288,580 against — passed, per its Form 8-K filed 2025-06-20 (Item 5.07). Of all 64,582,163 outstanding shares: 96% for, 0.5% against (97% of the company cast a for/against vote).

The 103 asset managers below cast 99.9% of the shares they voted on this item FOR (33,506,135 for, 12,323 against).

FOR 99.9%

FOR: 33,506,135 (99.9%)AGAINST: 12,323 (0.0%)ABSTAIN: 19,018 (0.1%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,348,469	0	For
T. Rowe Price	5,337,025	0	For
BlackRock	2,524,631	0	For
Fidelity	2,339,924	0	For
JPMorgan	1,820,643	0	For
State Street	1,161,666	68	For
Delaware/Macquarie	955,278	0	For
MUTUAL FUND SERIES TRUST	859,462	0	For
Invesco	621,899	0	For
Charles Schwab	604,993	0	For
TIAA	543,580	0	For
Manager Directed Portfolios	519,074	0	For
Jackson National	494,467	0	For
ACAP Strategic Fund	444,988	0	For
AllianceBernstein	382,517	0	For
Capital Group	367,124	0	For
Legg Mason	345,700	0	For
American Century	342,227	0	For
Columbia Threadneedle	336,059	0	For
Goldman Sachs	312,241	0	For
WILLIAM BLAIR FUNDS	298,044	0	For
Equitable	271,202	0	For
MFS	260,458	0	For
Principal	225,935	0	For
AB DISCOVERY GROWTH FUND, INC.	207,703	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

3. Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Jeffrey Albers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 44,683,223WITHHELD: 15,507,415

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Jeffery W. Albers”): 44,683,223 for, 15,507,415 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,582,163 outstanding shares: 69% for, 24% withheld (93% of the company cast a for/withheld vote).

The 101 asset managers below cast 100% of the shares they voted on this item FOR (27,931,271 for, 0 against).

FOR 83%ABSTAIN 17%

FOR: 27,931,271 (83.3%)ABSTAIN: 5,605,029 (16.7%)

Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,346,069	2,400	For
T. Rowe Price	5,315,475	21,550	For
BlackRock	2,524,631	0	For
Fidelity	2,339,724	200	For
JPMorgan	1,820,643	0	For
State Street	3,339	1,158,395	Abstain
Delaware/Macquarie	0	955,278	Abstain
MUTUAL FUND SERIES TRUST	859,462	0	For
Invesco	621,899	0	For
Charles Schwab	604,993	0	For
TIAA	543,580	0	For
Manager Directed Portfolios	519,074	0	For
Jackson National	381,683	112,784	For
ACAP Strategic Fund	0	444,988	Abstain
AllianceBernstein	382,517	0	For
Capital Group	367,124	0	For
Legg Mason	342,300	3,400	For
American Century	0	342,227	Abstain
Columbia Threadneedle	336,059	0	For
Goldman Sachs	291,734	20,507	For
WILLIAM BLAIR FUNDS	0	298,044	Abstain
Equitable	271,202	0	For
MFS	0	260,458	Abstain
Principal	77,655	148,280	Abstain
AB DISCOVERY GROWTH FUND, INC.	207,703	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

4. Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: John Tsai, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 6 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%

FOR: 47,572,890WITHHELD: 12,617,748

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: John Tsai, M.D.”): 47,572,890 for, 12,617,748 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,582,163 outstanding shares: 74% for, 20% withheld (93% of the company cast a for/withheld vote).

The 101 asset managers below cast 100% of the shares they voted on this item FOR (29,329,888 for, 0 against).

FOR 87%13%

FOR: 29,329,888 (87.5%)ABSTAIN: 4,206,412 (12.5%)

Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,346,069	2,400	For
T. Rowe Price	5,315,475	21,550	For
BlackRock	2,524,631	0	For
Fidelity	2,339,724	200	For
JPMorgan	1,820,643	0	For
State Street	1,160,253	1,481	For
Delaware/Macquarie	0	955,278	Abstain
MUTUAL FUND SERIES TRUST	859,462	0	For
Invesco	621,899	0	For
Charles Schwab	604,993	0	For
TIAA	543,580	0	For
Manager Directed Portfolios	519,074	0	For
Jackson National	381,683	112,784	For
ACAP Strategic Fund	0	444,988	Abstain
AllianceBernstein	382,517	0	For
Capital Group	367,124	0	For
Legg Mason	342,300	3,400	For
American Century	0	342,227	Abstain
Columbia Threadneedle	336,059	0	For
Goldman Sachs	291,734	20,507	For
WILLIAM BLAIR FUNDS	0	298,044	Abstain
Equitable	271,202	0	For
MFS	0	260,458	Abstain
Principal	77,655	148,280	Abstain
AB DISCOVERY GROWTH FUND, INC.	207,703	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

5. Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Mark Goldberg, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 6 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 46,734,594WITHHELD: 13,456,044

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Mark Goldberg, M.D.”): 46,734,594 for, 13,456,044 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,582,163 outstanding shares: 72% for, 21% withheld (93% of the company cast a for/withheld vote).

The 101 asset managers below cast 100% of the shares they voted on this item FOR (29,290,171 for, 0 against).

FOR 87%13%

FOR: 29,290,171 (87.3%)ABSTAIN: 4,246,129 (12.7%)

Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,346,069	2,400	For
T. Rowe Price	5,315,475	21,550	For
BlackRock	2,524,631	0	For
Fidelity	2,339,724	200	For
JPMorgan	1,820,643	0	For
State Street	1,160,253	1,481	For
Delaware/Macquarie	0	955,278	Abstain
MUTUAL FUND SERIES TRUST	859,462	0	For
Invesco	621,899	0	For
Charles Schwab	604,993	0	For
TIAA	543,580	0	For
Manager Directed Portfolios	519,074	0	For
Jackson National	381,683	112,784	For
ACAP Strategic Fund	0	444,988	Abstain
AllianceBernstein	382,517	0	For
Capital Group	367,124	0	For
Legg Mason	342,300	3,400	For
American Century	0	342,227	Abstain
Columbia Threadneedle	336,059	0	For
Goldman Sachs	291,734	20,507	For
WILLIAM BLAIR FUNDS	0	298,044	Abstain
Equitable	271,202	0	For
MFS	0	260,458	Abstain
Principal	77,655	148,280	Abstain
AB DISCOVERY GROWTH FUND, INC.	207,703	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

COMPENSATIONMajority of the votes cast: yes

Meeting held 2024-06-12 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 56,844,879AGAINST: 1,345,313

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Proposal 3: The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to compens”): 56,844,879 for, 1,345,313 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,582,163 outstanding shares: 88% for, 2% against (90% of the company cast a for/against vote).

The 2 asset managers below cast 2% of the shares they voted on this item FOR (876 for, 47,629 against).

AGAINST 98%

FOR: 876 (1.8%)AGAINST: 47,629 (98.2%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Brighthouse	0	47,629	0	0	Against
COLDSTREAM CAPITAL MANAGEMENT INC	876	0	0	0	For

Largest BLUEPRINT MEDICINES CORP. shareholders voting in 2024-2025

Ranked by the number of BLUEPRINT MEDICINES CORP. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 64,582,163 shares outstanding at the time of that meeting.

Top BLUEPRINT MEDICINES CORP. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	T. Rowe Price	20.11%
2	Vanguard	13.25%
3	BlackRock	7.50%
4	JPMorgan	7.42%
5	Avoro Capital Advisors LLC	5.98%
6	Fidelity	5.57%
7	State Street	5.52%
8	Wellington	4.02%
9	GEODE CAPITAL MANAGEMENT, LLC	2.37%
10	AllianceBernstein	2.29%

Reported BLUEPRINT MEDICINES CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BLUEPRINT MEDICINES CORP. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.39%	13F
Vanguard Group	10.28%	13F
T. Rowe Price	8.39%	13F
Pentwater Capital Management LP	6.04%	13G
Wellington Management	4.76%	13F
State Street	4.16%	13F
JPMorgan Chase	3.88%	13F
Geode Capital	2.36%	13F
FMR (Fidelity)	2.22%	13F
Invesco	1.52%	13F

Percentages above are of 64,582,163 shares outstanding, as reported by BLUEPRINT MEDICINES CORP. on its Form 10-Q dated 2025-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BLUEPRINT MEDICINES CORP.’s 10-Q dated 2025-04-29. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At BLUEPRINT MEDICINES CORP.'s shareholder meeting held 2025-06-18, in the 2024-2025 proxy season, 371 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 2,538 separate fund positions. On the most widely held item on that ballot — APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE… — the proposal passed with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BLUEPRINT MEDICINES CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-20.

BLUEPRINT MEDICINES CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).